

Statistical Methods for High Dimensional Biology STAT/BIOF/GSAT 540


Lecture 22 – Polygenic Risk Scores and Phenome-Wide Association
Studies (PheWAS)

March 31, 2021

Jessica Dennis, MSc, PhD

Assistant Professor of Medical Genetics

Dennis Lab in Complex Trait Genomics at UBC and BC Children's Hospital Research Institute




PhD in Epidemiology
from University of
Toronto

Postdoctoral Fellow in
Genetic Medicine at
Vanderbilt University
(Nashville, TN)



Genotype vs. Phenotype




Genotypes are the genetic make-up of an individual.




Phenotypes are the physical traits and characteristics of an individual and can be influenced by their genotype and/or by the environment.

Complex traits are multifactorial phenotypes.

Common disease common variant model motivating GWAS




15 Years of GWAS Discovery: Now What?



Learning Objectives

- 1) Explain what GWAS can and cannot tell us about the contribution of genetics to different human traits and diseases.
- 2) Calculate a polygenic risk score and describe potential applications.
- 3) Describe data elements contained within a biobank and the types of investigations made possible by these types of resources.

GWAS Study Design



Phenotype could be dichotomous, continuous, categorical, count, etc.

Array genotyping (typically >2 million SNP genotypes) followed by imputation to ~9 million SNP genotypes

Stringent multiple testing correction: $p < 5 \times 10^{-8}$

Out of scope: study design, phenotype and genotype QC



Activity: Explore GWAS catalogue (5 min.)

- Diagram: <https://www.ebi.ac.uk/gwas/diagram>
 - Hover over different dots to see the phenotypes studied
- Search Catalogue: <https://www.ebi.ac.uk/gwas/>
 - E.g., coronary artery disease
 - E.g., loneliness

Discussion:

- 1) What kinds of phenotypes have been studied in a GWAS?
- 2) What is the typical strength of association between genotype and phenotype (OR or Beta)?
- 3) Who is typically included in GWAS? What are typical sample sizes?
- 4) What insights do these results provide?

Genomics is failing on diversity




Self-reflection:
How diverse are the data you use in your research? How might this affect interpretation?

ASIDE: Race, ethnicity, and genetic ancestry

- “Race,” “ethnicity,” and “ancestry” are often used interchangeably, yet they have no universal definitions.
- **Race:** A culturally and politically charged term, for which definitions and meaning are context-specific. Race is related to individual and/or group identity and is often linked to stereotypes of visible physical attributes such as skin and hair pigmentation.
- **Ethnicity:** Describes people as belonging to cultural groups, usually on the basis of shared language, traditions, foods, etc.
- **(Genetic) ancestry:** a description of the population(s) from which an individual’s recent biological ancestors originated, as reflected in the DNA inherited from those ancestors. Genetic ancestry can be estimated via comparison of participants’ genotypes to global reference populations

GWAS discoveries can improve drug development




Trait	Gene with GWAS hits	Known or candidate drug
Type 2 Diabetes	<i>SLC30A8/KCNJ11</i>	ZnT-8 antagonists/Glyburide
Rheumatoid Arthritis	<i>PADI4/IL6R</i>	BB-CI-amidine/Tocilizumab
Ankylosing Spondylitis(AS)	<i>TNFR1/PTGER4/TYK2</i>	TNF-inhibitors/NSAIDs/fostamatinib
Psoriasis(Ps)	<i>IL23A</i>	Risankizumab
Osteoporosis	<i>RANKL/ESR1</i>	Denosumab/Raloxifene and HRT
Schizophrenia	<i>DRD2</i>	Anti-psychotics
LDL cholesterol	<i>HMGCR</i>	Pravastatin
AS, Ps, Psoriatic Arthritis	<i>IL12B</i>	Ustekinumab

GWAS can provide insights on genetic architecture

Genetic architecture of a trait refers to the total number of associated variants and, for each, the allele frequencies and the degree of risk conferred.


The concept of genetic architecture is applicable to any trait (e.g., Huntington's disease is caused by a rare, deterministic variant).

B. Relation between numbers of cases and genome-wide significant SNPs in GWAS^b



Visualizing GWAS results: Manhattan plot


GWAS hits



Learning Objectives

- 1) Explain what GWAS can and cannot tell us about the contribution of genetics to different human traits and diseases.
- 2) Calculate a polygenic risk score and describe potential applications.
- 3) Describe data elements contained within a biobank and the types of investigations made possible by these types of resources.

Most complex traits are polygenic



Burden of disease-causing factors can be modeled as a continuous liability in the population.

Disease is manifest in people whose burden exceeds some threshold.


We all carry some genetic burden for disease, which can be quantified by a polygenic score.

Polygenic Risk Scores (PRS)

Also known as: genetic risk scores; PGS

Method to predict an individual's genetic predisposition for disease

Simplest form:

$$PRS_i = \sum_{j=1}^m x_{ij} \hat{\beta}_j$$


The diagram illustrates the formula for the simplest form of a Polygenic Risk Score (PRS). The formula is $PRS_i = \sum_{j=1}^m x_{ij} \hat{\beta}_j$. Annotations include: an arrow from 'individual' pointing to the subscript i in PRS_i ; an arrow from 'SNP' pointing to the summation index j , with a sub-arrow pointing to m ; an arrow from 'SNP effect sizes' pointing to the coefficient $\hat{\beta}_j$; and an arrow from 'Genotype for individual i at SNP j ' pointing to the term x_{ij} .

Polygenic Scores (PRS): Example

$$PRS_i = \sum_{j=1}^m x_{ij} \hat{\beta}_j$$

PRS are allelic sums weighted by effect estimates from a discovery GWAS.

Discovery GWAS Summary Statistics	
SNP	Allele Effect ($\hat{\beta}$)
rs1	1.002
rs2	1.03
rs3	1.10
SNP _j	$\hat{\beta}_j$



Target Sample
(Genotyped patients)

ID	PRS
R2348	PRS= 0*1.002 + 2*1.03 + 0*1.10 ...
R9842	PRS= 1*1.002 + 1*1.03 + 0*1.10 ...

The number of SNPs included in the PRS calculation can range from a small number of genome-wide significant SNPs to several million

Activity: Calculate a PRS (3 min.)

$$PRS_i = \sum_{j=1}^m x_{ij} \hat{\beta}_j$$

Schizophrenia GWAS
Summary Statistics:

SNP	Allele Effect ($\hat{\beta}$)	P-value
rs1	0.52	7.2×10^{-12}
rs2	0.44	6.3×10^{-12}
rs3	0.35	9.3×10^{-10}
rs4	0.29	3.6×10^{-7}
rs5	0.27	7.2×10^{-6}
rs6	0.24	7.2×10^{-6}
rs7	0.17	7.2×10^{-4}

Sasha's
genotype data:

SNP	Allele copies (x)
rs1	2
rs2	0
rs3	1
rs4	1
rs5	2
rs6	1
rs7	0


Calculate a PRS for schizophrenia for Sasha, only including genome-wide significant SNPs

Discussion:

- 1) Now that you have calculated a PRS for schizophrenia in Sasha, what could you do with the score?


Applications of PRS

Within-Phenotype Association



Polygenic score for Phenotype₁


Cross-Phenotype Association




Polygenic score for Phenotype₁

What would this tell us?


Polygenicity vs. pleiotropy




Each gene has a distinct biological effect.



Polygenic trait: Many genes contribute to a single effect.



Pleiotropy: A gene has multiple effects.




Polygenic traits and pleiotropy


Pleiotropy describes the **genetic** effect of a single **gene** on multiple phenotypic traits. The underlying mechanism is **genes** that code for a product that is either used by various cells or has a cascade-like signaling function that affects various targets.

E.g., Mutations in the *CFTR* gene cause a multitude of symptoms in cystic fibrosis patients


Application of PRS: Within-phenotype associations




Application of PRS: Across-phenotype associations



Clinical Applications of PRS



Clinical Applications of PRS



Learning Objectives

- 1) Explain what GWAS can and cannot tell us about the contribution of genetics to different human traits and diseases.
- 2) Calculate a polygenic risk score and describe potential applications.
- 3) Describe data elements contained within a biobank and the types of investigations made possible by these types of resources.

Biobanks

Collections of biological specimens linked to phenotype data.

Used for health research.


What biobanks have you heard of?



Million Veteran Program



Biobanks: BioVU



SD: 2.8 million patient EHRs

BioVU: 285,000 patients EHRs linked to DNA samples

Average EHR length of BioVU patients is 10 years

UK Biobank – explore YouTube videos, website




Activity: Explore the UK Biobank Data Showcase (5 min.)

<http://biobank.ndph.ox.ac.uk/showcase/>

Discussion:

- 1) Who is included in these studies?
- 2) How generalizable are the results?
- 3) What would you do with these data?

Phenome-wide association study (PheWAS)



Activity: Explore polygenic burden associations across the human phenome (5 min.)

- http://mrcieu.mrsoftware.org/PRS_atlas/
 - E.g., PRS for “Neuroticism” in a PheWAS

Discussion:

- 1) What are the strengths and weaknesses of PheWAS?
- 2) What are the strengths and weaknesses of PRS-PheWAS?

Learning Objectives and Wrap-Up (5 min.)

- 1) Explain what GWAS can and cannot tell us about the contribution of genetics to different human traits and diseases.
- 2) Calculate a polygenic risk score and describe potential applications.
- 3) Describe data elements contained within a biobank and the types of investigations made possible by these types of resources.